Clinical trial
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the…
NCT00246662 · Sunesis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00246662 |
|---|---|
| Title | Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies |
| Official title | Phase 1b Open-Label, Multicenter Clinical Study of the Safety and Activity of Intravenous Administration of SNS-595 in Patients With Advanced Hematologic Malignancies |
| Lead sponsor | Sunesis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Acute, Nonlymphocytic, Myeloid, Chronic, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Vosaroxin |
| Enrollment | 75 |
| Start date | Nov 14, 2005 |
| Primary completion | Dec 23, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Oct 31, 2005 |
| Last update posted | Mar 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: